


## 1. Participant flow



Group 1: A single intravenous dose of 40 mg/kg infused over 60 minutes

Group 2: A single nebulization of 90 mg

Group 3: Five once-daily nebulizations of 90 mg

**2. Baseline Characteristics**

	<b>Group 1 (N=18)</b>	<b>Group 2 (N=18)</b>	<b>Group 3 (N=12)</b>	<b>Overall (N=48)</b>
Age (years)				
n	18	18	12	48
Mean (SD)	31.8 (7.09)	32.2 (7.79)	40.1 (11.45)	34.0 (9.13)
Median	29.5	32.0	43.0	32.0
Min, Max	22, 46	19, 53	19, 54	19, 54
Sex, n (%)				
Male	9 (50.0)	10 (55.6)	7 (58.3)	26 (54.2)
Female	9 (50.0)	8 (44.4)	5 (41.7)	22 (45.8)
Race, n (%)				
White	14 (77.8)	13 (72.2)	10 (83.3)	37 (77.1)
Asian	2 (11.1)	0	2 (16.7)	4 (8.3)
Black or African American	1 (5.6)	3 (16.7)	0	4 (8.3)
Other	1 (5.6)	2 (11.1)	0	3 (6.3)
Ethnicity, n (%)				
Not Hispanic or Latino	18 (100.0)	18 (100.0)	12 (100.0)	48 (100.0)
Height (cm)				
n	18	18	12	48
Mean (SD)	173.78 (9.765)	172.00 (8.885)	173.50 (6.961)	173.04 (8.664)
Median	173.00	173.00	174.00	173.00
Min, Max	157.0, 190.0	155.0, 188.0	161.0, 183.0	155.0, 190.0
Weight (kg)				
n	18	18	12	48
Mean (SD)	73.91 (13.529)	72.76 (12.075)	74.27 (10.780)	73.57 (12.106)
Median	74.30	73.05	73.25	73.70
Min, Max	50.2, 97.2	52.5, 91.3	62.4, 94.1	50.2, 97.2
Body Mass Index (kg/m <sup>2</sup> )				
n	18	18	12	48
Mean (SD)	24.32 (3.254)	24.53 (3.201)	24.63 (2.952)	24.48 (3.097)
Median	23.10	24.95	24.65	24.40
Min, Max	19.8, 30.1	19.3, 29.5	20.7, 31.0	19.3, 31.0

Note:

Group 1: A single intravenous dose of 40 mg/kg infused over 60 minutes; Group 2: A single nebulization of 90 mg; Group 3: Five once-daily nebulizations of 90 mg. Percentages were based on the number of participants in the Safety Analysis Population.

**3. Primary Outcome Measure: Treatment Emergent Adverse Events (TEAEs)**

	<b>Group 1 (N=18)</b>	<b>Group 2 (N=18)</b>	<b>Group 3 (N=12)</b>
Participants with any treatment-emergent adverse event	14	8	9
Participants with nebulization-related TEAE*	NA	0	0
Number of serious adverse events	0	0	0
<b>Total Number of TEAEs</b>	<b>27</b>	<b>12</b>	<b>12</b>
<b>Event by MedDRA System Organ Class:</b>			
Eye disorders			1
Gastrointestinal disorders			1
General disorders and administration site conditions	11	3	1
Infections and infestations	1	1	2
Injury, poisoning and procedural complications	1	3	2
Nervous system disorders	7	3	5
Renal and urinary disorders	1		
Respiratory, thoracic and mediastinal disorders	5	2	
Skin and subcutaneous tissue disorders	1		

\*Occurring within 2-hours of completing nebulization

Group 1: A single intravenous dose of 40 mg/kg infused over 60 minutes

Group 2: A single nebulization of 90 mg

Group 3: Five once-daily nebulizations of 90 mg